Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 9/20 | 1.00 |
| ▸ | MEN1 | O00255 | 8/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 8/20 | 1.00 |
| ▸ | CASP1 | P29466 | 6/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 1.00 |
| ▸ | HPGD | P15428 | 6/20 | 1.00 |
| ▸ | CASP7 | P55210 | 5/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 1.00 |
| ▸ | MAPT | P10636 | 5/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 5/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 4/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 1.00 |
| ▸ | RECQL | P46063 | 3/20 | 1.00 |
| ▸ | BRCA1 | P38398 | 2/20 | 1.00 |
| ▸ | BLM | P54132 | 2/20 | 1.00 |
| ▸ | TST | Q16762 | 1/20 | 1.00 |
| ▸ | USP2 | O75604 | 3/20 | 0.97 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.97 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.94 |
| ▸ | LMNA | P02545 | 2/20 | 0.94 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Harmalol SCHEMBL30163266 | 1.00 | KDM4E (1.00) | KDM4EMEN1KMT2ACASP1ALDH1A1 | |
| Harmalol SCHEMBL2516758 | 0.99 | KDM4E (1.00) | KDM4EMEN1KMT2ACASP1ALDH1A1 | |
| Harmalol SCHEMBL30285851 | 0.99 | KDM4E (1.00) | KDM4EMEN1KMT2ACASP1ALDH1A1 | |
| Harmalol SCHEMBL18489068 | 0.97 | KDM4E (1.00) | KDM4EMEN1KMT2ACASP1ALDH1A1 | |
| Harmalol SCHEMBL3759482 | 0.97 | KDM4E (1.00) | KDM4EMEN1KMT2ACASP1ALDH1A1 | |
| Harmalol SCHEMBL7669597 | 0.93 | KDM4E (0.87) | KDM4EMEN1KMT2ACASP1ALDH1A1 | |
| SCHEMBL1520498 | 0.88 | KDM4E (0.79) | KDM4EMEN1KMT2ACASP1ALDH1A1 | |
| Harmalol SCHEMBL9480810 | 0.88 | KDM4E (0.77) | KDM4EMEN1KMT2ACASP1ALDH1A1 | |
| Harmaline SCHEMBL29626541 | 0.80 | KDM4E (1.00) | KDM4EMEN1KMT2ACASP1ALDH1A1 | |
| Harmaline SCHEMBL199260 | 0.80 | KDM4E (1.00) | KDM4EMEN1KMT2ACASP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 508 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137652-A1 | Composition Comprising Non-Phosphorylated Tryptamine | SINTALICA S R L (IT) | 2026-05-21 | — | — | US | claimed |
| EP-4638419-A1 | NON-HALLUCINOGENIC TRYPTAMINE COMPOUNDS, PREPARATION, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | Sintalica S.r.l. (IT) | 2025-10-29 | — | — | EP | claimed |
| EP-4601655-A1 | DELIVERY SYSTEM FOR THE CONTROLLED RELEASE OF PSYCHEDELIC COMPOUND, PHARMACEUTICAL COMPOSITION AND USES THEREOF | Sintalica S.r.l. (IT) | 2025-08-20 | — | — | EP | claimed |
| EP-4601627-A1 | COMPOSITION COMPRISING NOT PHOSPHORYLATED TRYPTAMINE, ANTIOXIDANTS, AND SUPPLEMENTS, AND PHARMACEUTICAL USES THEREOF | Sintalica S.r.l. (IT) | 2025-08-20 | — | — | EP | claimed |
| EP-4601665-A1 | COMPOSITION COMPRISING TRYPTAMINES AND MAOIS COMPOUNDS SELECTED FROM ?-CARBOLINE INHIBITORS, AND PHARMACEUTICAL USES THEREOF | Sintalica S.r.l. (IT) | 2025-08-20 | — | — | EP | claimed |
| WO-2024254645-A1 | COMPOSITION AND METHOD TO TREAT, AMELIORATE OR PREVENT A PSYCHOLOGICAL, NEUROLOGICAL OR INFLAMMATORY DISORDER, AND METHOD FOR PREPARING COMPOSITION | Psychae Therapeutics Pty Ltd (AU) | 2024-12-19 | — | — | WO | claimed |
| US-20240294986-A1 | PRECISION MEDICINE FOR SCHIZOPHRENIA AND PSYCHOTIC DISORDERS: OBJECTIVE ASSESSMENT, RISK PREDICTION, PHARMACOGENOMICS, AND REPURPOSED DRUGS | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2024-09-05 | — | — | US | claimed |
| US-20240254533-A1 | METHODS FOR PRODUCING TRYPTAMINE DERIVATIVES | OCTARINE BIO APS (DK) | 2024-08-01 | — | — | US | claimed |
| WO-2024134619-A1 | NON-HALLUCINOGENIC TRYPTAMINE COMPOUNDS, PREPARATION, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | SINTALICA S.R.L. (IT) | 2024-06-27 | — | — | WO | claimed |
| EP-4355423-A1 | PRECISION MEDICINE FOR SCHIZOPHRENIA AND PSYCHOTIC DISORDERS: OBJECTIVE ASSESSMENT, RISK PREDICTION, PHARMACOGENOMICS, AND REPURPOSED DRUGS | Indiana University Research and Technology Corporation (US) | 2024-04-24 | — | — | EP | claimed |
| US-20100285001-A1 | Method and Compositions Related to Synergistic Responses to Oncogenic Mutations | UNIVERSITY OF ROCHESTER (US) | 2010-11-11 | — | — | US | claimed |
| EP-2227233-A2 | IDO INHIBITORS | Newlink Genetics (US) | 2010-09-15 | — | — | EP | claimed |
| EP-2188630-A2 | METHODS AND COMPOSITIONS RELATED TO SYNERGISTIC RESPONSES TO ONCOGENIC MUTATIONS | THE UNIVERSITY OF ROCHESTER (US) | 2010-05-26 | — | — | EP | claimed |
| US-20100063085-A1 | METHOD OF TREATING LEARNING IMPAIRMENT IN DOWN'S SYNDROME SUBJECTS | UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE | 2010-03-11 | — | — | US | claimed |
| EP-2151441-A1 | Beta-carbolin-derivates as substrates for an enzyme | Julius-Maximilians-Universität Würzburg (DE) | 2010-02-10 | — | — | EP | claimed |
| WO-2009073620-A2 | IDO INHIBITORS | NEWLINK GENETICS (US) | 2009-06-11 | — | — | WO | claimed |
| WO-2009045443-A2 | METHODS AND COMPOSITIONS RELATED TO SYNERGISTIC RESPONSES TO ONCOGENIC MUTATIONS | THE UNIVERSITY OF ROCHESTER (US) | 2009-04-09 | — | — | WO | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
| US-5591738-A | Method of treating chemical dependency using β-carboline alkaloids, derivatives and salts thereof | NDA INTERNATIONAL, INC. (US) | 1997-01-07 | — | — | US | claimed |
| EP-0046270-A1 | Novel derivatives of bio-affecting phenolic compounds and pharmaceutical composition containing them | INTERx RESEARCH CORPORATION (US) | 1982-02-24 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260137652-A1 | Composition Comprising Non-Phosphorylated Tryptamine | HTR2B, BDNF, HTR3B | KDM4E 4470/4885MEN1 2822/4885KMT2A 4380/4885 |
| US-20100063085-A1 | METHOD OF TREATING LEARNING IMPAIRMENT IN DOWN'S SYNDROME SUBJECTS | GRIK5, CHAT, ACHE | KDM4E 3006/4885MEN1 3369/4885KMT2A 891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.